GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
GBI Health Data Intelligence Suite
Full Life-Cycle Solutions for Pharmaceuticals

Powered by global drug pipeline data, the Competitive Landscape Analysis solution enables multidimensional analysis across drugs, targets, indications, and technologies. It helps R&D teams identify strategic opportunities, prioritize investments, and make more informed development decisions.

Drawing on data from six major global clinical trial registries, the Clinical R&D Insights solution provides deep visibility into global trial activity and protocol designs, helping teams optimize clinical development strategies and trial execution.

Drawing on data covering the National Reimbursement Drug List (NRDL), public procurement and tendering, Huiminbao (commercial health insurance), Patient Assistance Programs (PAPs), and healthcare policies and regulations, the Market Access Strategy solution supports market access planning, pricing analysis, and regional opportunity assessment to accelerate commercialization and market access.

Built on comprehensive researcher profiles, the GBI KOL/HCP Management solution enables researcher identification, segmentation, academic influence analysis, and collaboration network mapping, helping Medical Affairs, Marketing, and Sales teams improve researcher engagement and operational efficiency.
Aggregating industry news and in-depth reports to help pharma companies stay ahead.
On November 19, 2026, Merck (NYSE: MRK) and Isomorphic Labs, an AI-first drug design and development company, announced a research collaboration that brings together Isomorphic Labs’ AI approach to drug discovery with Merck’s rich proprietary data resources and deep discovery experience.
On November 19, 2026, GSK plc (LSE/NYSE: GSK) announced that velzatinib, a novel, highly selective KIT inhibitor, has received Orphan Drug Designation (ODD) from Japan’s Ministry of Health, Labour and Welfare for the treatment of gastrointestinal stromal tumour (GIST).
On November 19, 2026, Innogen Pharmaceutical Group Co., Ltd. (2591.HK) announced that the company has entered into an exclusive license agreement with Arcera Life Sciences Ltd. ("Arcera") to advance the development and commercialization of efsubaglutide alfa in emerging markets worldwide.
On 16 November 2026, TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, announced it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH.
On November 19, 2026, HUTCHMED (Nasdaq/LSE: HCM; HKEX: 13) announced that the China National Medical Products Administration (NMPA) has granted simultaneous approval for two New Drug Applications (NDAs) of SYVIK (sovleplenib), a novel, highly selective oral spleen tyrosine kinase (Syk) inhibitor: (1) for the treatment of adult patients with chronic primary immune thrombocytopenia (ITP) who have had an insufficient response to at least one prior therapy; and (2) for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an insufficient response to prior corticosteroid therapy.
On November 20, 2026, Hengrui Pharma announced that its fosrolapitant and palonosetron for injection (trade name: Ruitanning) has been approved by the National Medical Products Administration for a new indication: the prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy (MEC) in adult patients.

Curated by expert analysts, offering in-depth analysis of emerging industry trends and the competitive landscape.

Scan the QR code to follow the GBIHealth WeChat Official Account for industry news, live webinars, thematic reports, and more.
Our clients are drawn from across pharma, medical device firms, CROs/CDMOs, investors, consulting firms, and others
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Contact Us